TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00774631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild induced hypothermia (32-34°C)
Description: Mild Induced hypothermia:~Investigators are advised to use the cooling techniques as used in patients with cardiac arrest. Thus, the choice of cooling method will be left to investigators. Hypothermia will be induced by cold saline infusion as described in appendix 5 \[6, 48\]. Core temperature will be monitored by oesophageal probe and maintained between 32°C and 34°C during 48 hours and followed by strictly passive rewarming. During this phase of treatment, patients will receive deep sedation associated with neuromuscular blockers. Centers participating to the trial will have expertise in cooling methods.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local recommendations and guidelines
Description: Investigational procedure:~This study evaluates the impact of mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming according to recommendations described in appendix. All treatment will be according to local recommendations and guidelines of medical societies and literature. Physicians are advised to use these recommendations; however, the best treatment option for the individual patient should be used.~Controls will receive standard care and will be also be deeply sedated for 48 hours.
Study: NCT02501603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Afatinib 40mg daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 80mg/m2 IV weekly (day 1,8,15)
Study: NCT00213148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Description: Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 5 mg
Description: Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole 10 mg
Description: Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate 50 mg
Description: Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate 100 mg
Description: Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).
Study: NCT01954485

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant placement with a final prosthetic abutment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implant placement with a final prosthetic abutment
Study: NCT03964896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Complete survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone calls
Study: NCT03204006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine preinduction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline
Description: normal saline preinduction
Study: NCT02180659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual buprenorphine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo implants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sublingual placebo tablets
Study: NCT03721614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioMime™ Morph - Sirolimus Eluting Coronary Stent System
Description: Study Device :- BioMime™ Morph - Sirolimus Eluting Coronary Stent System Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience family Everolimus Coronary Stent Systems
Description: Active Control Device :- Xience family Everolimus Coronary Stent Systems Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
Study: NCT03841591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Women with GDM will receive insulin and tailored according to their blood glucose levels to achieve glycemic control. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Women with GDM will receive metformin and tailored according to their blood glucose levels to achieve glycemic control. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of weight gain
Description: Body weight will be measured monthly from the start of treatment till delivery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of weight gain
Description: Body weight will be measured monthly from the start of treatment till delivery.
Study: NCT01863394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening by mothers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Screening by community health workers
Study: NCT02986048

Intervention type: OTHER
Intervention: Proton Beam Therapy
Description: Intervention is not assigned. Only patient data is being collected
Study: NCT04281147

Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Follow clinical administration

Intervention type: DRUG
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Follow clinical administration
Study: NCT03878368

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Intervention soup with dietary sulforaphane

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Control soup without dietary sulforaphane
Study: NCT00322517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU014813
Description: 100 mg capsule/day for 6 cycle of 21 days
Study: NCT03602976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: weight-based dosing
Study: NCT03288428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: patient controlled analgesia with Nalbuphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: patient controlled analgesia with Morphine
Study: NCT01909999

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Soft tissues sutures were done using absorbable polygalactin 910 suture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-operative care
Description: Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days); sodic dipyrone 500mg (6-6 hours/3 days); 0.12% Chlorhexidine mouthwash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative care
Description: Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days); sodic dipyrone 500mg (6-6 hours/3 days); 0.12% Chlorhexidine mouthwash
Study: NCT01569620

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best clinical practices plus culturally targeted print materials
Description: This intervention arm includes best clinical practices (or usual care at MSSM) and the culturally relevant print materials developed for this study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best clinical practices plus standard print materials
Description: This intervention arm includes best clinical practices (or usual care at MSSM) and the standard CRC screening print materials developed by the Centers for Disease Control (CDC).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best clinical practices alone
Description: This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
Study: NCT02083536

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Fractionated Whole Abdominal Radiation Therapy
Description: A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy will consist of 6 cycles of Docetaxel. Each cycle will follow standard of care and will be scheduled every 3 weeks ± 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle, chemotherapy will consist of Docetaxel 60 mg/m² infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration).
Study: NCT00476827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab(Avastin) 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle. until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPT-11
Description: CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine Tartrate
Description: Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.until progression or unacceptable toxicity develops
Study: NCT03370042

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: semilunar coronally positioned flap with free gingival graft

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: semilunar coronally positioned flap alone
Study: NCT02114606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge™ Cell Collection Device
Description: The Cytosponge™ Cell Collection Device (Cytosponge) is intended to collect surface cells from the esophagus. The device consists of a swallowable capsule, which dissolves in the body cavity, releasing a self-expandable sponge. The sponge is then retrieved from the esophagus using an attached cord. During the retrieval process, the sponge collects cells from the most superficial layer of the esophageal mucosa. Once removed from the body cavity, the sponge and cells are retained for investigation and/or testing. The Cytosponge™ Cell Collection Device (Cytosponge) received 510(k) clearance from the FDA on November 26, 2014 (K142695). The Cytosponge ™ Cell Collection device is a Class II product under 21 CFR 874.4710 esophagoscope (flexible or rigid) and accessories.
Study: NCT02275663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: G-CSF
Study: NCT02822898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9% in Glucose 5% with 40mEq Potassium
Description: NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucion 5%
Description: Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h
Study: NCT01013194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Fetal Liver Cell Transplantation
Description: Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.~Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.~Cell infusion: between 5 and 10x10\^8 cells. Number of sessions: up to 2.
Study: NCT01466127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Liquid metered-dose nasal spray, 30 IUs, administered once.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched nasal spray placebo
Study: NCT01841814

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Bone densitometry.
Study: NCT02582099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin nasal irrigation
Description: Nasal wash with gentamicin solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline nasal irrigation
Description: Nasal wash with normal saline solution
Study: NCT00208377

Intervention type: DEVICE
Group type: OTHER
Intervention: DePuy ASR Hip System
Description: A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
Study: NCT03738371

Intervention type: OTHER
Intervention: In situ simulation
Description: Team involved in thrombectomy procedures will be trained by in situ simulation. Simulation will reproduce the initial step of a thrombectomy procedure, i.e from from the installation of the patient to the percutaneous punch by the neuroradiologist. Simulation will be followed by a debriefing focused on the team performance. Three in situ simulation sessions will be realized by each team.
Study: NCT02373358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group yoga intervention
Description: Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety \& boundaries, strength \& power, assertiveness, intuition, trust, \& community) using mindfulness, breath work, and physical yoga poses.
Study: NCT03234738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TP-271
Description: multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is sterile 0.45% saline randomized 3:1 to receive

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is sterile 0.45% saline randomized 3:1 to receive

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is sterile 0.45% saline randomized 3:1 to receive

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is sterile 0.45% saline randomized 3:1 to receive

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is sterile 0.45% saline randomized 3:1 to receive
Study: NCT02665871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: one dose of Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: one dose of Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03533062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin A
Description: botox A injection trigonal or trigonal sparing with trial of anticholinergics 6 months post operative for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin A
Description: botox A injection trigonal or trigonal sparing with trial of anticholinergics 6 months post operative for 3 months
Study: NCT01387204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
Study: NCT01891851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350 200 mg
Description: Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir 100 mg
Description: Each patient will receive 100 mg (1 capsule) of ritonavir twice daily orally from Day 1 until Day 15 of Session 2
Study: NCT01226719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg, 60-90 minute IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2, 2-hour IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 125 mg/m2, 1-hour IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m2, 2-hour IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 3200 mg/m2 IV, 48-hour continuous infusion every two weeks
Study: NCT05827627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation
Description: Midwifery student directing the birth of a fetus with frank breech presentation.

Intervention type: OTHER
Group type: OTHER
Intervention: simulation
Description: Midwifery student directing the birth of a fetus with frank breech presentation.
Study: NCT03903666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nocturnal gaz exchanges measurement
Description: Nocturnal gaz exchanges at patient's home BRIEF neuropsychological questionnaire VINELAND-II neuropsychological questionnaire Clinical OSA assessment Dysautonomia assessment
Study: NCT03096665

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: Point of care blood analysis obtained from skin puncture
Study: NCT01868633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03320681

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Stimulation
Description: Percutaneous electrical nerve stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: Dry Needling Stimulation
Description: Percutaneous nerve stimulation
Study: NCT02611622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LUMA ENT™

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Demographic and Patient Satisfaction Survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Demographic and Patient Satisfaction Survey
Study: NCT01302821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenovirus-p53 transduced dendritic cell vaccine
Description: The Ad.p53 DC vaccine will be injected intradermally (through the skin) into four separate sites. The patient's vaccine will be the same dose throughout the study.
Study: NCT03545438

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LIB003
Description: LIB003 or placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LIB003
Description: LIB003 or placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LIB003
Description: LIB003 or placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LIB003
Description: LIB003 or placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LIB003
Description: LIB003 or placebo
Study: NCT01302821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1-methyl-D-tryptophan
Description: Each treatment cycle is comprised of 21 days. The treatment is continuous with no breaks in between cycles. Patients would not be allowed to take any tryptophan containing supplements while participating on this study.
Study: NCT03194919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endre: a digital smoking cessation counsellor
Description: A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen \& Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).